why is there a semaglutide shortage The Ozempic Over Digital Health Law Firm |
Description
The SUSTAIN trial series documented that semaglutide users lost 515% of body weight depending on dose and duration, with these outcomes reproducible across multiple healthcare settings and patient populations
2014;222:T1T9
In a cross-sectional study presented at the European Association for the Study of Diabetes annual meeting and published in Diabetes, Obesity and Metabolism , researchers surveyed adults with obesity who were using semaglutide (Ozempic/Wegovy, Novo Nordisk) or tirzepatide (Mounjaro, Eli Lilly) and asked about changes in their appetite, satiety and sensory perception after starting an incretin-based therapy
Published 2014 Mar 7
Always check your prescription label to confirm that B12 is a listed ingredient
Severe stomach pain, dehydration, or allergic reactions need prompt medical care
